- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02229760
Effect of Steady State TPV/r on Intracellular Concentrations of Zidovudine and Carbovir for Patients With HIV
August 28, 2014 updated by: Boehringer Ingelheim
Effect of Steady State TPV/r 500 mg/200 mg on Intracellular Concentrations of Zidovudine Triphosphate and Carbovir Triphosphate
To determine the effect of steady-state tipranavir 500 mg/ritonavir 200 mg (TPV/r) on intracellular concentrations of zidovudine triphosphate (ZDV-TP) and carbovir triphosphate (CBV-TP) and plasma viral load
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
3
Phase
- Phase 2
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed informed consent before study participation
- Age >18 and <60 years
- Female patients of child-bearing potential who use a barrier contraceptive method for at least 12 weeks before administration of study medication, during the study and for 28 days after administration of study medication has ended and who have a negative pregnancy test result
- Ability to swallow capsules without difficulty
- A Body Mass Index (BMI) between 18 and 29 kg/m2
- Reasonable probability of completing the study
- A medical history, physical examination, and electrocardiogram (ECG) before entering the study
- Agreement to abstain from alcohol from Day -2 to Day 24
- Agreement to abstain from ingesting grapefruit, grapefruit juice, Seville oranges or orange marmalade from Day -2 to Day 24
- Negative urine drug screen for drugs of abuse
- Documented HIV-1 RNA load (by PCR) at screening of <50 copies/mL for at least 3 months and on a stable ZDV or ABC regimen for at least 6 months. Acceptable documentation included laboratory data, letter, or verbal report from another provider noted in the patient's records
- All HIV-infected patients must be TPV naïve and must not have received a PI based regimen within 6 months of enrollment
Exclusion Criteria:
- Female patients who had a positive serum pregnancy test during the screening period of Day -14 to Day -7 or who plan to breast-feed at time (Day 0 to 30 after TPV/r administration)
- Use of any other investigational medicine within 30 days before Day 0
- Use of any known CYP3A4 altering drug (i.e., phenothiazines, cimetidine, barbiturates, ketoconazole, fluconazole, rifampin, steroids and herbal medications) within 30 days before Day 0. No antibiotics were permitted within 10 days before Day 0
- Ingestion of grapefruit, grapefruit juice, Seville oranges, or orange marmalade within 2 days of study entry (Day 0)
- Blood or plasma donations (>100 mL total) for research or altruistic reasons within 30 days before Day 0
- Seated systolic blood pressure either <100 mm Hg or >150 mm Hg; resting heart rate either <50 beats/minute or >90 beats/minute
- History of any illness (including malabsorption, irregular food intake, gastrointestinal intolerance, or allergy) that, in the opinion of the investigator, might confound the results of the study or pose additional risks in administering TPV/r
- Any acute illness within 2 weeks before Day 0
- Patients who were currently taking any over-the-counter medication within 7 days before Day 0, or who were currently taking any prescription drug that, in the opinion of the investigator (in consultation with the BI medical monitor or pharmacokineticist), would have interfered with either the absorption, distribution, or metabolism of TPV or ritonavir
- Hypersensitivity to TPV, ritonavir, or sulfonamide containing drugs, or antiretroviral drugs (marketed or experimental use as part of clinical research studies)
- Sulfonamide allergy, that in the opinion of the investigator, might confound the results of the study or pose additional risks in administering TPV/r
- Any laboratory value outside the normal reference range that is of clinical relevance at screening, according to the judgment of the investigator (i.e., aspartate aminotransferase and alanine aminotransferase levels 2.5-fold and 2.5-fold higher than the upper normal limit, respectively)
- Based on the compliance diary, the patient had less than 100% documented compliance for 7-14 days of background Antiretroviral (ARV) (i.e., ZDV and ABC) medications before Day -5 to 0 (visit 2)
- Use of any protease inhibitors (i.e., fosamprenavir, amprenavir, indinavir, saquinavir, lopinavir, ritonavir, atazanavir, and nelfinavir) within 6 months of enrollment
- Patients who are co-infected with active Hepatitis B and/or C as determined by hepatitis serology.
- Use of any anti-platelet medications (e.g. aspirin, dipyridamole, clopidogrel, or any over the counter anti-platelet medicine).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TPV/r (Tipranavir co-administered with low dose ritonavir)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUC0-12h (Area under curve) of intracellular ZDV-TP
Time Frame: Up to 12 hours after drug administration
|
Up to 12 hours after drug administration
|
AUC0-12h (Area under curve) of carbovir-TP
Time Frame: Up to 12 hours after drug administration
|
Up to 12 hours after drug administration
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients with clinical significant findings in vital sings
Time Frame: Up to 14 days after last drug administration
|
Up to 14 days after last drug administration
|
Number of patients with clinical significant findings in physical examinations
Time Frame: Up to 14 days after last drug administration
|
Up to 14 days after last drug administration
|
Number of patients with clinical significant findings in laboratory measurements
Time Frame: Up to 14 days after last drug administration
|
Up to 14 days after last drug administration
|
Concentration of Zidovudine (ZDV) in plasma
Time Frame: Up to 14 days after drug administration
|
Up to 14 days after drug administration
|
Concentration of Abacavir (ABC) in plasma
Time Frame: Up to 14 days after drug administration
|
Up to 14 days after drug administration
|
Concentration of Tipranavir (TPV) in plasma
Time Frame: Up to 14 days after drug administration
|
Up to 14 days after drug administration
|
Concentration of ritonavir in plasma
Time Frame: Up to 14 days after drug administration
|
Up to 14 days after drug administration
|
Cmax (Maximum observed concentration)
Time Frame: Up to 14 days after drug administration
|
Up to 14 days after drug administration
|
Cp12h (Trough plasma concentration)
Time Frame: Up to 14 days after drug administration
|
Up to 14 days after drug administration
|
AUC0-12h (Area under curve)
Time Frame: Up to 14 days after drug administration
|
Up to 14 days after drug administration
|
Number of patients with adverse events
Time Frame: Up to 14 days after last drug adminnistration
|
Up to 14 days after last drug adminnistration
|
Percentage of patients with viral load (VL) <50
Time Frame: Up to 14 days after last drug adminnistration
|
Up to 14 days after last drug adminnistration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2006
Primary Completion (Actual)
September 1, 2007
Study Registration Dates
First Submitted
August 28, 2014
First Submitted That Met QC Criteria
August 28, 2014
First Posted (Estimate)
September 1, 2014
Study Record Updates
Last Update Posted (Estimate)
September 1, 2014
Last Update Submitted That Met QC Criteria
August 28, 2014
Last Verified
August 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Ritonavir
- Tipranavir
Other Study ID Numbers
- 1182.109
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Tipranavir capsules
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Reata, a wholly owned subsidiary of BiogenAbbVie; Friedreich's Ataxia Research AllianceActive, not recruitingFriedreich AtaxiaUnited States, Australia, Austria, Italy, United Kingdom
-
Reata, a wholly owned subsidiary of BiogenAbbVieCompletedMItochondrial MyopathiesUnited States, Denmark
-
Reata, a wholly owned subsidiary of BiogenTerminatedConnective Tissue Disease-Associated Pulmonary Arterial HypertensionUnited States, Spain, Japan, Australia, United Kingdom, Canada, Germany, Belgium, Argentina, Israel, Mexico, Brazil, Czechia, Netherlands, Philippines
-
Chinese Academy of Medical Sciences, Fuwai HospitalNot yet recruiting
-
AbbottQuintiles, Inc.Terminated
-
Montefiore Medical CenterCompletedIrritable Bowel SyndromeUnited States
-
Chinese Academy of Medical Sciences, Fuwai HospitalNational Natural Science Foundation of ChinaRecruiting